Spark Therapeutics Revenue and Competitors

Location

$122.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Spark Therapeutics's estimated annual revenue is currently $300.3M per year.(i)
  • Spark Therapeutics received $350.0M in venture funding in August 2017.
  • Spark Therapeutics's estimated revenue per employee is $248,000
  • Spark Therapeutics's total funding is $122.8M.

Employee Data

  • Spark Therapeutics has 1211 Employees.(i)
  • Spark Therapeutics grew their employee count by 0% last year.

Spark Therapeutics's People

NameTitleEmail/Phone
1
Chief Staff, Legal & Corporate Compliance and Head Legal OperationsReveal Email/Phone
2
Chief Staff to the Chief People OfficerReveal Email/Phone
3
CEOReveal Email/Phone
4
Chief Staff to the Chief Patient Supply OfficerReveal Email/Phone
5
Chief Staff - Development & Product StrategyReveal Email/Phone
6
Chief Staff - ResearchReveal Email/Phone
7
Chief Staff, ResearchReveal Email/Phone
8
Head Medical AffairsReveal Email/Phone
9
Head Talent Development & Organizational EffectivenessReveal Email/Phone
10
Head Corporate Facilities and WorkplaceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Spark Therapeutics?

At Spark Therapeutics, we dont follow footsteps. We create the path. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is seemingly impossible to others, but not to us: Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable until now. Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. We are seeking talented individuals with diverse experiences, abilities and interests who have the curiosity, courage and drive to reimagine a new health care paradigm. Join us on a journey through uncharted territory seeking to bring gene therapy for genetic diseases to people worldwide. The resilience of the people we serve is our inspiration to break barriers, as we strive to turn genes into medicine for those with inherited diseases. Know that working at Spark Therapeutics is not just another job; it is a once-in-a-lifetime opportunity. We embrace the challenges before us and the uncertainty inherent in them. Ultimately, we are working to create a world free of genetic disease. To learn more about Spark and our open positions, visit www.sparktx.com. You can also find us on Twitter at @Spark_tx.

keywords:N/A

$122.8M

Total Funding

1211

Number of Employees

$300.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Spark Therapeutics News

2022-04-20 - Diagnostic Enzymes Sales Market Size 2022-2030| Key ...

Spark Therapeutics; Genzyme; Aldevron; Kaneka Eurogentec; Biovian; Brammer; Cobra Biologics; FinVector Vision Therapies; Oxford Gene Technology; Vigene...

2014-11-28 - Spark Therapeutics adds regulatory insider to support gene therapy for retinal degeneration

Romuald Corbau, former research project leader for Pfizer’s gene therapy program for the hepatitis C virus, joined as Spark’s translational research lead to help support the company’s pipeline of gene therapies. Earlier this month Spark received breakthrough therapy designation for its SPK-RPE6 ...

2014-07-10 - Sofinnova appears to be bulking up a healthcare venture fund to $110 million

Sofinnova Ventures has a robust active portfolio. Some of its more notable funding rounds include participation in a $72.8 million Series B round with Spark Therapeutics, a $55 million C round with Coherus Bio Sciences and a $50 million round with Principia Biopharma. Calls for comment on the u ...

2014-05-27 - Spark Therapeutics Completes $72.8M Series B Financing

Spark Therapeutics, a Philadelphia, PA-based late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, completed a $72.8m Series B financing. The round was led by Sofinnova Ventures, with participation from new investors Brookside Capital, Deerfield Man ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$312.7M1241N/AN/A
#2
$300M12471%N/A
#3
$384.1M12476%N/A
#4
$318.5M1264N/AN/A
#5
$75M12734%N/A

Spark Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-05-28$72.8MBSofinnova VenturesArticle
2017-08-07$350.0MUndisclosedJ.P. Morgan Securities LLCArticle